Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immunogenicity of a candidate Ebola vaccine in adults; completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• GlaxoSmithKline Ebola vaccine candidate

Snippet

Sponsor: GlaxoSmithKline | Conditions: Virus Diseases | Phase 2 | Status: COMPLETED | Results posted: 2018-01-04